Based on the ruling, products that are legal federally as well as at the state level can be reimbursed, which is a huge step forward, given that older policies prevented all cannabis-based substances from being reimbursed by insurance. However, we must be careful to take note of the nuances here; the ruling doesn’t treat cannabis as a primary medical treatment just yet but rather they are considered “specialized, non-primarily health-related benefits” by the Centers for Medicare and Medicaid Services (CMS).